News for Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma's Board of Directors a

Puma Biotechnology's undervaluation & promising pipeline with neratinib & alisertib trials make it a 'Buy.' Explore growth catalysts & future prospects now!

Discover key insights from Puma Biotechnology's Q1 2025 earnings report, including NERLYNX sales trends, clinical trial updates, and future financial...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsMariann Ohanesian - Senior Director...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Puma Biotechnolog

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NPBYI.OQ - Puma Biotechnology IncQ1 2025 Puma Biotechnology Inc Earnings CallMay 08, 2025 / 08:

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors ap

Puma Biotechnology (PBYI) has entered a strategic partnership with Er-Kim to distribute NERLYNX in specific regions within Eastern Europe and Central Asia. NERL

This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can reduce the risk of cancer recurre

**media[609925]**

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the Ameri

Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. ( SINT), an

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma's Board of Directors

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Total Revenue: $59.1 million for Q4 2024.Product Revenue Net: $54.4 million for Q4 2024.Royalty Revenue: $4.7 million for Q4 2024.Net Income (GAAP): $19.3 mill

Feb 27, 2025 / 09:30PM GMTOperator Good afternoon. My name is Darryl, and I will be your conference call operator today. (Operator Instructions) As a reminder,

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsMariann Ohanesian – Senior...